Pacylex Pharmaceuticals Publishes a New Myristoylation Inhibitor Mechanism of Anti-Cancer Activity in Molecular Cancer Therapeutics ...

VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis ...

Belzutifan outperformed everolimus in patients with previously treated, advanced clear-cell renal cell carcinoma in the phase 3 LITESPARK-005 trial.

Monoamine oxidase inhibitors (MAOIs) are the oldest class of antidepressants. Although they have largely been replaced by newer medications with fewer side effects, they are still used to treat some ...

Expert Rev Anticancer Ther. 2012;12(12):1545-1547. Many other clinical trials aimed at optimizing sequential therapy in mRCC are currently ongoing and their results are eagerly awaited in order to ...

For example, glutathione peroxidase 4 and glutaminase inhibitors can inhibit pyrimidine synthesis and increase reactive oxygen species levels in VHL-deficient RCC cells. In addition, the release of ...

Wu M, Xiong H, Xu Y, et al. Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis. British Journal of Ophthalmology ...

Fruzaqla is a selective oral inhibitor of all three VEGF receptors (-1, -2 and -3). VEGFR inhibitors play a pivotal role in blocking tumour angiogenesis. Fruzaqla was designed to have enhanced ...

Fruquintinib is a selective oral inhibitor of all three VEGF receptors (VEGFR‑1, ‑2 and ‑3). VEGFR inhibitors play a pivotal role in inhibiting tumor angiogenesis. Fruquintinib was designed to have ...

FRUZAQLA is a selective oral inhibitor of all three VEGF receptors (-1, -2 and -3). VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. FRUZAQLA was designed to have enhanced ...

About FRUZAQLA (fruquintinib) FRUZAQLA is a selective oral inhibitor of all three VEGF receptors (-1, -2 and -3). VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. FRUZAQLA was ...